Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI.

MLA

Sims, Matthew, et al. “Integrated Safety Analysis of Phase 3 Studies for Investigational Microbiome Therapeutic, SER-109, in Recurrent CDI.” Antimicrobial Stewardship & Healthcare Epidemiology, vol. 3, June 2024, pp. s44–45. EBSCOhost, https://doi.org/10.1017/ash.2023.281.

APA

Sims, M., Berenson, C., Cohen, S., Wang, E., Hohmann, E., Nathan, R., Odio, A., Cook, P., Brady, K., Lombardi, D., Memisoglu, A., De, A., Hasson, B., Lashner, B., Korman, L., Grimard, D., Gutierrez, J. C. M., McGovern, B., & Moltke, L. V. (2024). Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI. Antimicrobial Stewardship & Healthcare Epidemiology, 3, s44–s45. https://doi.org/10.1017/ash.2023.281

Chicago

Sims, Matthew, Charles Berenson, Stuart Cohen, Elaine Wang, Elizabeth Hohmann, Richard Nathan, Alberto Odio, et al. 2024. “Integrated Safety Analysis of Phase 3 Studies for Investigational Microbiome Therapeutic, SER-109, in Recurrent CDI.” Antimicrobial Stewardship & Healthcare Epidemiology 3 (June): s44–45. doi:10.1017/ash.2023.281.